Requip-XL Dosage
Generic name: ROPINIROLE HYDROCHLORIDE 2mg
Dosage form: tablet, film coated, extended release
Drug class: Dopaminergic antiparkinsonism agents
Medically reviewed by Drugs.com. Last updated on Jul 10, 2024.
General Dosing Recommendations
- •
- REQUIP XL extended-release tablets are taken once daily, with or without food.
- •
- Tablets must be swallowed whole and must not be chewed, crushed, or divided.
- •
- If a significant interruption in therapy with REQUIP XL has occurred, retitration of therapy may be warranted.
Dosing for Parkinson’s Disease
The recommended starting dose of REQUIP XL is 2 mg taken once daily for 1 to 2 weeks, followed by increases of 2 mg/day at weekly or longer intervals, based on therapeutic response and tolerability. Monitor patients at least weekly during dose titration. Too rapid a rate of titration may lead to the selection of a dose that does not provide additional benefit, but increases the risk of adverse reactions.
In fixed-dose studies designed to characterize the dose response to REQUIP XL, there was no additional therapeutic benefit shown in patients with advanced stage Parkinson’s disease taking daily doses greater than 8 mg/day, or with early stage Parkinson’s disease taking doses greater than 12 mg/day. Although the maximum recommended dose of REQUIP XL is 24 mg, patients with advanced Parkinson’s disease should generally be maintained at daily doses of 8 mg or lower and patients with early Parkinson’s disease should generally be maintained at daily doses 12 mg or lower.
REQUIP XL should be discontinued gradually over a 7-day period.
Renal Impairment
No dose adjustment is necessary in patients with moderate renal impairment (creatinine clearance of 30 to 50 mL/min). The recommended initial dose of REQUIP XL for patients with end-stage renal disease on hemodialysis is 2 mg once daily. Further dose escalations should be based on tolerability and need for efficacy. The recommended maximum total daily dose is 18 mg/day in patients receiving regular dialysis. Supplemental doses after dialysis are not required. The use of REQUIP XL in patients with severe renal impairment without regular dialysis has not been studied.
Switching from Immediate-Release Ropinirole Tablets to REQUIP XL
Patients may be switched directly from immediate-release ropinirole to REQUIP XL tablets. The initial dose of REQUIP XL should approximately match the total daily dose of the immediate-release formulation of ropinirole, as shown in Table 1.
Immediate-Release Ropinirole Tablets |
REQUIP XL Tablets |
Total Daily Dose (mg) |
Total Daily Dose (mg) |
0.75 to 2.25 |
2 |
3 to 4.5 |
4 |
6 |
6 |
7.5 to 9 |
8 |
12 |
12 |
15 |
16 |
18 |
18 |
21 |
20 |
24 |
24 |
Following conversion to REQUIP XL, the dose may be adjusted depending on therapeutic response and tolerability.
More about Requip XL (ropinirole)
- Check interactions
- Compare alternatives
- Reviews (7)
- Drug images
- Side effects
- During pregnancy
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Sinemet
Sinemet is used to treat symptoms of Parkinson's disease, such as muscle stiffness, tremors ...
Cogentin
Cogentin is used for extrapyramidal reaction, parkinson's disease
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Requip
Requip is used to treat symptoms of Parkinson's disease, such as stiffness, tremors and muscle ...
Mirapex
Mirapex (pramipexole) treats the symptoms of Parkinson's disease and is also used to treat Restless ...
Exelon
Exelon (rivastigmine) is used to treat dementia caused by Alzheimer's or Parkinson's disease ...
Gocovri
Gocovri (amantadine) is used in the treatment of Parkinson's disease. Includes Gocovri side ...
Inbrija
Inbrija is an inhaled medicine used to treat the symptoms of Parkinson's disease. Includes side ...
Rivastigmine
Rivastigmine systemic is used for alzheimer's disease, lewy body dementia, parkinson's disease
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.